Skip to content
Clinical Trials – home

Dexamethasone: An Important Medication for Multiple Myeloma Treatment

4 / 16
trials open to patients / all trials
21+
Countries

In short

Dexamethasone, a potent corticosteroid, is being extensively studied in clinical trials for the treatment of multiple myeloma. These trials aim to evaluate its effectiveness when used in combination with other drugs to improve outcomes for patients with newly diagnosed, relapsed, or refractory multiple myeloma. The studies explore various drug combinations and treatment strategies to find the most effective approaches for managing this challenging blood cancer.

At a glance

Drug Name
Dexamethasone Ph. Eur.
Formulation
Tablet, 2.0mg
Main Indications
Multiple Myeloma (newly diagnosed, relapsed, or refractory)
Common Combinations
VRd, DPd, DVd, Rd, PVd, Kd
Trial Phases
Phase 2 and Phase 3
Primary Endpoints
Progression-Free Survival, Minimal Residual Disease negative rate
Patient Populations
Newly diagnosed, transplant-ineligible, relapsed/refractory after 1-4 prior lines of therapy
Administration Route
Oral use
Max Daily Dose
40mg (in some trials)
Treatment Duration
Varies by trial, from months to years

What is Dexamethasone?

Dexamethasone is a powerful corticosteroid medication that plays a crucial role in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. It is known by various names, including DEXAMETHASONE PH. EUR. and is available in tablet form for oral use.

How Dexamethasone is Used in Multiple Myeloma Treatment

Dexamethasone is widely used in the treatment of multiple myeloma due to its anti-inflammatory and immunosuppressive properties. It helps in several ways:

  • Reducing inflammation in the body
  • Suppressing the immune system to slow down the growth of cancer cells
  • Alleviating symptoms associated with multiple myeloma, such as bone pain and fatigue
  • Enhancing the effectiveness of other anti-myeloma drugs when used in combination therapies

Combination Therapies Including Dexamethasone

Dexamethasone is often used in combination with other medications to treat multiple myeloma. Some common combination therapies include:

  • VRd: Bortezomib (Velcade), Lenalidomide (Revlimid), and Dexamethasone
  • DRd: Daratumumab, Lenalidomide, and Dexamethasone
  • DPd: Daratumumab, Pomalidomide, and Dexamethasone
  • EPd: Elotuzumab, Pomalidomide, and Dexamethasone
  • PVd: Pomalidomide, Bortezomib, and Dexamethasone

These combinations are used in various stages of multiple myeloma treatment, including newly diagnosed cases, relapsed or refractory disease, and as maintenance therapy.

Dosage and Administration

The dosage of dexamethasone can vary depending on the specific treatment regimen and the patient's individual needs. In the clinical trials reviewed, the following information was noted:

  • Dexamethasone is typically administered orally in tablet form
  • The maximum daily dose can be up to 40 mg
  • Treatment duration can vary, with some regimens lasting up to 172 weeks (approximately 3.3 years)

It's important to note that the exact dosage and schedule should be determined by your healthcare provider based on your specific condition and treatment plan.

Potential Side Effects

While dexamethasone is an effective treatment for multiple myeloma, it can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Changes in blood sugar levels
  • Mood changes or irritability
  • Insomnia
  • Increased appetite and weight gain
  • Fluid retention
  • Osteoporosis (with long-term use)
  • Muscle weakness

It's crucial to discuss any side effects you experience with your healthcare provider, as they may be able to adjust your treatment or provide ways to manage these effects.

Precautions and Considerations

When taking dexamethasone, there are several important precautions and considerations to keep in mind:

  • Inform your doctor about any allergies or hypersensitivities you may have to dexamethasone or its components
  • Dexamethasone may interact with other medications, so it's important to inform your healthcare provider about all medications you're taking
  • Long-term use of dexamethasone may suppress your immune system, increasing your risk of infections
  • If you're pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits of dexamethasone with your doctor
  • Do not stop taking dexamethasone abruptly without consulting your healthcare provider, as this can lead to withdrawal symptoms

Dexamethasone is a powerful medication that plays a crucial role in the treatment of multiple myeloma. While it can be highly effective, it's important to use it under close medical supervision and to communicate openly with your healthcare team about any concerns or side effects you may experience.

Questions people often ask

Conditions where Dexamethasone Ph. Eur. is being studied

Each condition opens its own overview and trial list

Trials with Dexamethasone Ph. Eur.

Recruiting trials first

See all 16 →
Quick filters
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).